Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ENPEP | Q07075 | 9/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051532 | 1.00 | ALDH1A1 (0.53) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL30011402 | 0.97 | ALDH1A1 (0.50) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL934499 | 0.93 | ALDH1A1 (0.59) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL30445952 | 0.93 | ALDH1A1 (0.59) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL1863400 | 0.93 | ALDH1A1 (0.59) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL2543429 | 0.93 | ALDH1A1 (0.59) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL934498 | 0.93 | ALDH1A1 (0.59) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL30052816 | 0.90 | ALDH1A1 (0.56) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL29353917 | 0.89 | ALDH1A1 (0.51) | ALDH1A1ENPEPMMEACECPA1 | |
| SCHEMBL29906310 | 0.89 | ALDH1A1 (0.51) | ALDH1A1ENPEPMMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | ALDH1A1 4801/4885ENPEP 26/4885MME 286/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | ALDH1A1 4801/4885ENPEP 26/4885MME 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.